CAPR·Nasdaq·US
Capricor
Capricor is a clinical-stage biotechnology company focused on cell and exosome-based therapeutics for rare diseases, especially Duchenne muscular dystrophy. Its lead program is Deramiocel, an allogeneic cardiac-derived cell therapy, and recent filings indicate little to no current revenue after prior collaboration and milestone recognition.
Recent Activity
Updated Oct 10, 2026
–Capricor Therapeutics presented positive open-label extension data from its HOPE-3 trial on upper limb function in Duchenne muscular dystrophy patients at the 2026 World Muscle Society Congress.
–In a 24-month crossover analysis, patients who started deramiocel after a year on placebo slowed upper limb decline by 76% compared with their own prior year.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.